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Up to now, limited and contradictory results have been published on the role of 
prognostic values of lipid profile molecules including: HDL (High Density 
Lipoprotein), LDL (Low Density Lipoprotein), TG (Triglyceride), Total Cholesterol 
and PCSK9 (Proprotein Convertase SubtilisinKexin type 9) molecule in occurrence 
and development of Parkinson’s disease (PD). The aim of this study was to 
investigate the role of lipid profile and PCSK9 in patients with PD and to compar it 
with healthy individuals. 
Methods and Results 
In the present case-evidence study, 32 individuals diagnosed with PD were 
compared with 32 healthy individuals. After receiving the  participant's consent 
forms, 5 ml blood was taken from  
vein and the level of HDL(High -Density Lipoprotein), LDL (Low-Density 
Lipoprotein), TG (Triglyceride),Total Cholesterol and PCSK9 in the blood samples 
were measured. The Elisa method was used for measuring PCSK9 level in blood 
serum. Data were analyzed using SPSS17 software. The P values smaller than 0.05 
were considered significant. 
The mean age of participants in the PD and control group was 56.9±8.8 and 
53.7±10.1 years respectively (P>0.05). Twenty seven individuals (87.1%) and 13 
individuals (41.9%) in the PD group and control group were men, respectively. The 
remaining participants were women (P=0.000). LDL level (84.2±24.9 ml/dl vs. 
105.5±16.8, P=0.000), HDL (45.5±8.7 ml/dl vs. 51.1±9.5 ml/dl, P=0.000), total 
cholesterol (155.3±31.2 ml/dl vs. 192.8±32.5 ml/dl P=0.000) were lower and TG 
level was higher in the PD group (133.3±79.3 ml/dl vs. 131.2±58.6 ml/dl, P=0.9) 
compared with the control group. PCSK9 level was higher in the PDgroup, but no 
significant difference was found (141.6±70 vs. 129.7±51 ng/ml, P=0.5). 
Conclusions 
Our findings showed that individuals with PD have lower level of HDL, LDL and 
total cholesterol compared with the control group, but PCSK9 levels were same in 
both groups.  
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